CEPI’s call for new individuals to join its Scientific Advisory Committee, or SAC—an external expert group providing guidance and recommendations to CEPI on R&D programmes and broader outbreak response efforts—is now open through 23 January 2026.Interested individuals can apply using our online form.
CEPI is recruiting global health professionals with extensive experience across relevant scientific and product development disciplines to join its SAC, and is particularly interested in applicants with expertise in AI, process development and manufacturing, and late-stage development.
Successful applicants’ scientific input, guidance and challenge will be critical in the shaping and implementation of the CEPI 3.0 strategy, guided by our mission to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they are accessible to all people in need.
New members’ terms will last three years, starting on 1 May 2026, with the first face-to-face meeting taking place on 20-21 October, 2026. Virtual participation will be made available for anyone unable to travel at this time.
Advancing vaccines and other countermeasures to stop the next outbreak
Founded in 2017 in response to the West African Ebola epidemic, CEPI is a public–private partnership dedicated to preventing future epidemics and pandemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats, and to ensure they are accessible to all who need them.
Over its first decade, CEPI has advanced more than 30 vaccine candidates against priority pathogens including Ebola, Lassa fever, Nipah virus, MERS, Rift Valley fever, Chikungunya, and Disease X. This work has delivered multiple world firsts, including the first-ever licensed Chikungunya vaccine, the first Nipah and Lassa fever vaccines to enter Phase II clinical trials, and the first Rift Valley fever vaccine to reach Phase II testing in an endemic region. We’ve additionally invested in platform technologies and enabling sciences to accelerate responses to both known and unknown threats. CEPI also played a central role in the COVID-19 response, building one of the world’s largest COVID-19 vaccine portfolios and co-leading COVAX, which helped deliver nearly two billion doses to 146 countries.
Through CEPI 2.0, the organisation set out the 100 Days Mission, a goal—embraced by G7 and G20 leaders—to accelerate the development of safe and effective vaccines against new threats in just 100 days. CEPI 3.0 now builds on this ambition, translating a decade of experience into an operational strategy focused on preparedness, delivery, resilience, and impact. By 2031, CEPI aims to demonstrate that the world can be ready for today’s epidemic risks and be better prepared to respond rapidly and equitably to the pandemics of tomorrow.
Experts to advise and guide the coalition
The SAC is an independent body within CEPI and is one of CEPI’s core governance groups alongside the Board, Investors Council, and Joint Coordination Group.
Working in a personal capacity, members of the SAC meet three times per year (twice in person and once virtually) to provide world-class scientific input and recommendations to CEPI staff and the Board. This includes advising on a diversity of issues related to vaccine research and development and manufacturing to support the effective implementation of CEPI’s strategic objectives. The SAC has no executive function in the operations of CEPI but plays a critical advisory role.
Requests for guidance from the SAC may include but are not limited to:
- Recommending pathogens against which CEPI will focus vaccine development efforts.
- Advising on change of priorities in the event of public health emergencies or significant events caused by emerging pathogens with epidemic potential.
- Updating the CEPI Leadership on important developments in science and technology relevant to CEPI’s mission.
- Advising on the scope, objectives, and approach of Calls for Proposals (CFPs) and the process for selection of fundable proposals.
- Reviewing proposals submitted in response to CEPI CFPs.
- Monitoring scientific and development progress of CEPI’s vaccine portfolio and reviewing the overall quality of CEPI’s scientific operations.
- Participating in external communications activities designed to raise awareness of, and explain the science behind, CEPI’s work.
Apply today
The review process will begin immediately after closure of the application window on Friday, 23 January 2026, at 23:59 GMT. The decision on appointments to the SAC will be made by the CEPI Board.
Candidates will be notified of the outcome of their application in March/April, 2026. If you have any questions, please contact [email protected].
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate
Sinergium paves the way for Latin American mRNA vaccines with new preclinical study
